Background: First choice treatment for chronic Q fever is doxycycline plus hydroxychloroquine. Serum doxycycline concentration (SDC) .5 lg/mL has been associated with a favourable serological response, but the effect on clinical outcomes is unknown.
Introduction
Q fever is caused by the intracellular Gram-negative bacterium Coxiella burnetii. After primary infection, approximately 60% of patients remain asymptomatic. The remaining patients develop illnesses such as flu-like symptoms or pneumonia. 1 A small proportion of patients develop chronic Q fever after primary infection. 1 In contrast to acute Q fever, chronic Q fever is a potential lifethreatening disease. Most often, it leads to endocarditis, infection of vascular prostheses or arterial aneurysms. 1 The recommended first-line treatment for chronic Q fever is doxycycline combined with hydroxychloroquine for at least 18 months, or alternatively doxycycline combined with a quinolone. [2] [3] [4] [5] Culturing of C. burnetii
is not routinely performed in practice, because it is difficult and only allowed in laboratories with a Biosafety Level 3 facility. [6] [7] [8] Therefore, monitoring of treatment effect mainly depends on measurement of antibody titres, monitoring by PCR for C. burnetii in blood or tissue, and follow-up of the patient's clinical condition. 1 To assess the adequacy of doxycycline dosage and compliance with therapy, measurement of serum doxycycline concentration (SDC) is a potential tool. In two clinical studies, SDC .5 lg/mL was associated with favourable serological response, and in another study, higher SDC to MIC ratios were associated with rapid decline in phase I IgG antibodies to C. burnetii. [9] [10] [11] This can be explained by doxycycline being more effective at higher concentrations, or resistance leading to decreased effectiveness in patients with lower SDC. [12] [13] [14] In two reports, resistance was reported in 6%-23% of isolates. 9, 14 The effect of measuring SDC on clinical endpoints such as complications and mortality and PCR-positivity, has not been studied before. By evaluating data from a nationwide cohort of chronic Q fever patients, we aimed to assess the effect of treatment when dosage was based on SDC, as performed in clinical practice, for these clinical endpoints in chronic Q fever patients treated with doxycycline and hydroxychloroquine.
Patients and methods
Data from the Dutch national chronic Q fever database were used: in this database, detailed data are recorded regarding the treatment of patients with proven or probable chronic Q fever diagnosed since the start of the Dutch Q fever outbreak (1 January 2007) . Using these data, we retrospectively assessed the effect of measuring SDC in patients who were treated with doxycycline and hydroxychloroquine for at least 12 weeks. As this is a retrospective study and action taken by clinicians on SDC results is not standardized, we could not study the effect of SDC values on clinical outcomes: clinicians intervene based on SDC values and may aim for higher values in patients with more severe disease, which leads to bias. Therefore, we studied the effect of a treatment strategy in which dosage adjustment and coaching regarding compliance was based on SDC.
Data collection and inclusion of patients
The design of the Dutch national chronic Q fever database was approved by the Medical Ethics Committee of the University Medical Center in Utrecht. This database contains complete follow-up data of all chronic Q fever patients 18 years of age in the Netherlands from 1 January 2007 to 1 May 2016, from 28 hospitals in the Netherlands (see Acknowledgements). Diagnosis and classification of chronic Q fever was based on the Dutch chronic Q fever consensus group criteria. 15 Clinicians identified patients based on a positive PCR for C. burnetii in serum or tissue and/or C. burnetii phase I IgG 1:1024. Patients with a serological profile and clinical condition matching acute Q fever were excluded. The Dutch chronic Q fever consensus group criteria discriminate between proven, probable and possible chronic Q fever. For this study, only patients with proven or probable chronic Q fever were included. Possible chronic Q fever patients were not included because the presence of clinical relevant infection in possible chronic Q fever patients is questionable and these patients do not have an indication for treatment; therefore, evaluation of treatment-related aspects and outcomes is impossible.The observation period for all patients ended on 1 May 2016.
Laboratory testing
Microbiological testing consisted of an indirect fluorescent-antibody assay (IFA) for phase I and II IgG against C. burnetii in plasma or serum (Focus Diagnostics, Inc., Cypress, CA, USA or Fuller Diagnostics, LLC, Anchorage, AK, USA). Titration of antibody levels was carried out at different hospital sites with dilutions on a binary scale with a cut-off of 1:32. Furthermore, PCR for C. burnetii DNA in serum or plasma and, if applicable, in tissue samples was performed (NucliSENS easyMAG; bioMérieux, Marcy l'Etoile, France). All SDC measurements were performed in the apothecary laboratory of the Jeroen Bosch Hospital in 's-Hertogenbosch, with the exception of one measurement of a patient from the Laurentius Hospital in Roermond. SDCs were quantified by HPLC. Measurement of doxycycline concentrations was performed after extraction from serum samples. In brief, 500 lL of serum was mixed with 500 lL of internal standard (2.5 mg/L dantrolene) and 2 mL monosodium phosphate/sulphate buffer. After gently mixing for 30 s, 8 mL of dichloromethane was added for extraction. The mixture was vortexed for 1 min and centrifuged at 3200 g for 5 min. The organic phase was transferred to a clean tube and evaporated. The residue was dissolved in 200 lL of mobile phase (i.e. distilled water ! 200 lL triethylamine ! 1250 lL phosphoric acid 85%). The sample was passed through the chromatograph column (flow rate of 0.6 mL/min). The HPLC system was by Hitachi and equipped with a diode-array detector (DAD) set at 348 nm. The column was a LiChrospher 100-5 RP-18e, 120%4 mm, from Knauer.
Definitions
The primary outcome of this study was the first disease-related event (a new complication of chronic Q fever or chronic Q fever-related mortality) during treatment or within 1 year after the end of treatment with doxycycline plus hydroxychloroquine. The hazard for occurrence of the first event only was studied in case of multiple consecutive events, as multiple events within individuals are not independent of each other. Secondary outcomes were: (i) all-cause mortality during treatment or within 1 year after the end of treatment with doxycycline plus hydroxychloroquine; and (ii) PCRpositivity during treatment, defined as a new positive PCR, having been negative for at least 3 months or a persistent positive PCR for more than 6 months during treatment with doxycycline plus hydroxychloroquine. PCRpositivity was used as an outcome because the presence of C. burnetii is considered proven in the case of a positive PCR. 1 The cut-off period of 1 year after the end of treatment was chosen because complications and diseaserelated mortality most often occur far inside this time frame. 16 Conditions considered as complications of chronic Q fever were rupture or dissection of aneurysm; acute symptomatic aneurysm; arterial fistula; endoleak of vascular prosthesis; spondyl(odisc)itis or osteomyelitis; (cardiac) abscess; cerebrovascular accident (haemorrhagic or ischaemic)/transient ischaemic attack; cardiac arrest or tamponade during pericarditis. Cause of death was reviewed by two investigators in all cases (C. P. B.-R. and S. E. van R.) and classification of the relationship between death and chronic Q fever was performed by reaching a consensus. Death was defined as related to chronic Q fever in case of active disease and a cause of death related to chronic Q fever. Active disease was defined as C. burnetii phase I IgG 1:1024 or positive PCR on serum or tissue. Cause of death related to chronic Q fever was defined as sepsis/feverish episode with no other cause; brain infarct or haemorrhage during endocarditis or due to cerebral aneurysm; arterial fistula; ruptured/dissected aneurysm; heart failure; fatal arrhythmia or cardiac arrest during endocarditis; surgical complications; side effects of antibiotic therapy; clinical deterioration during active disease with no other cause; chronic Q fever as cause of death proven by autopsy; unknown cause in the presence of chronic Q fever-related complications or unknown cause without adequate chronic Q fever treatment.
Side effects and severity of side effects, reasons for discontinuing and/or switching and dosage adjustments of antibiotics were reported. Furthermore, SDC values were reported in order to determine whether clinicians were aiming for SDC values .5 lg/mL, as is currently recommended in the literature by experts.
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Statistical methods
Data were retrieved from electronically stored patient records, or paper records if applicable, and stored anonymously in a Microsoft Access 2010 database. Continuous data were compared by independent samples t-test (Welch method) or ANOVA (if .2 categories). For ANOVA with significant results, post hoc analysis was performed by Tukey's range test. In univariable analysis, survival curves were compared with a Log-rank or TaroneWare test as appropriate. Multivariable analysis was performed with a Cox proportional hazards model. Covariates were selected based on previously identified predictors for the outcomes. 16 For disease-related events, age, presence of prosthetic material before diagnosis of chronic Q fever and Serum doxycycline concentrations in chronic Q fever JAC PCR-positivity during disease were encountered as covariates in the model. Age and presence of prosthetic material before diagnosis of chronic Q fever were encountered as covariates in the model for all-cause mortality and PCR-positivity during treatment. For all-cause mortality, cause-specific HR was calculated. For first disease-related event and PCR-positivity, subdistribution HR was calculated to account for right-censoring. Left-censoring was accounted for by stratification for the presence of complications before the start of treatment. As the effect of measuring SDC on primary and secondary outcomes may vary per hospital, leading to correlation of patients from the same hospital, a random effect for hospital was included by fitting shared-frailty terms in the model (assuming a Gaussian distribution of the frailty parameter). If patients were treated in multiple hospitals consecutively, the hospital in which the patient was diagnosed was selected. An additional analysis was performed to assess whether intensity of patient care explained the results, as the effect of measuring SDC could be a proxy for intensity of patient care. The ratio of number of phase I IgG antibody titre measurements and follow-up duration in weeks was considered a proxy for intensity of patient care. We compared this ratio for patients with treatment based on SDC and patients without treatment based on SDC, and for patients with and without primary and secondary outcomes. Finally, we repeated Cox-regression analysis for primary and secondary outcomes, with adjustment for the ratio of number of phase I IgG antibody titre measurements and follow-up duration in weeks in the model. The Cox-regression models were fitted with the 'cmprsk' and 'survival' packages in RStudio, version 3.2.2.
17 The proportional hazard assumption was verified with both formal tests and graphically, using Schoenfeld residuals. Level of significance was set at a P value of ,0.05. Descriptive data were generated in SPSS, version 21.0. Figures were made in RStudio, version 3.2.2.
Results
Of 439 chronic Q fever patients in the database, we identified 201 eligible patients with proven or probable chronic Q fever treated with doxycycline and hydroxychloroquine for at least 12 weeks (Figure 1 ). In 167 patients (83%), SDC was measured. The remaining 34 patients (17%) were treated without measurement of SDC. Doxycycline and hydroxychloroquine was the first treatment for chronic Q fever in 188 patients (94%). Characteristics of all patients and number of primary and secondary outcomes in total and per subgroup are summarized in Table 1 .
SDC measurement
In 167 patients, 652 SDC measurements were taken (median 3 SDC per patient, IQR 2-5). The first SDC was .5 lg/mL in 106 patients (63%), all with a doxycycline dosage of 200 mg/day. In 145 patients (87%), at least one SDC of .5 lg/mL was measured.
Doxycycline dose was adjusted in 68 patients (41%) in whom SDC was measured: it was increased in 55 patients (81%), decreased in 4 patients (6%) and both increased and decreased in 9 patients (13%). In patients with increased dosage and SDC measured before and afterwards (n " 59), mean SDC before the first increase was 4.1 lg/mL and mean SDC after the first increase was 5.9 lg/mL ( Figure 2 ).
Mean SDC was studied for different subgroups of patients. In both patients with and without primary or secondary outcomes, overall mean SDC was .5 lg/mL (Figure 3 ). Mean SDC values were higher for patients with the outcomes, compared with those without the outcomes. For disease-related events and all-cause mortality, this difference was not significant. For patients with PCRpositivity, this difference was significant (P " 0.02). Furthermore, during treatment with different doxycycline dosages, overall mean SDC was .5 lg/mL with no significant differences in SDC between dosages (P " 0.70). All measured SDC values with corresponding doxycycline dosages are shown in Figure 4 , with multiple measurements within individuals included. The number of patients with and without measurement of SDC diagnosed in time is shown in Figure 5 : no evident increase in the proportion of patients with SDC measurements in time was observed. In patients without SDC measurement, doxycycline dose was increased in one patient (3%); all other patients used doxycycline 200 mg/day.
SDC in relation to primary and secondary outcomes
The primary outcome (first disease-related event) occurred in 36 patients (22%) with SDC measurement and in 13 patients (38%) without SDC measurement. As for secondary outcomes, all-cause mortality occurred in 23 patients (14%) with SDC measurement and 5 patients (15%) without SDC measurement. PCRpositivity occurred in 19 patients (11%) with SDC measurement and 1 patient (3%) without SDC measurement. Kaplan-Meier survival curves for disease-related events and all-cause mortality are shown in Figure 6 . In univariable survival analysis, there was a significant difference in disease-related events between patients with SDC measured and patients without SDC measured, with a lower risk for the outcome for those with SDC measured (P " 0.008). No significant differences in all-cause mortality were observed between patients with and without SDC measured (P " 0.64).
In multivariable analysis, treatment based on SDC was associated with a significantly lower risk for disease-related events (HR 0.51, 95% CI 0.26-0.97, P " 0.04). It was not associated with a lower risk for all-cause mortality during treatment or within 1 year after the end of treatment (HR 0.93, 95% CI 0.35-2.51, P " 0.89) or van Roeden et al.
PCR-positivity during treatment (HR 5.87, 95% CI 0.73-46.98, P " 0.10) (see Table 2 ).
Additional adjustment for intensity of patient care
The ratio of number of phase I IgG antibody titre measurements and follow-up duration in weeks was significantly higher in patients with SDC measured (0.071 versus 0.057, P " 0.02). The ratio was significantly higher in patients that died (of all causes) in comparison to patients that survived (0.093 versus 0.021, P " 0.001). No differences in this ratio were found between patients with and without disease-related events (0.076 versus 0.067, P " 0.11) or PCR-positivity during treatment (0.077 versus 0.068, P " 0.21). In Cox-regression analysis, correction for the ratio of number of phase I IgG antibody titre measurements and follow-up duration in weeks did not significantly change the HR estimates and CI for primary and secondary outcomes.
Side effects
Patients treated based on SDC reported side effects in 78% (n " 131), in patients without measurement of SDC, side effects occurred in 62% (n " 21); see Table 3 . Mean maximum dosages were not significantly different in patients experiencing side effects and in patients stopping due to side effects in comparison to those who did not (mean 232 versus 233, P " 0.97 and mean 228 versus 235, P " 0.36). Moreover, there was no significant difference in the mean SDC value for those with side effects (mean 6.18 lg/mL) compared with those without side effects (mean 5.76 lg/mL, P " 0.37). (10) 19 ( 7.14 0 Figure 3 . Differences in SDC for patients with and without primary and secondary outcomes. The differences in first disease-related event and all-cause mortality are not statistically significant. The difference for PCR failure is statistically significant (P " 0.02). Dosage was unknown during 11 SDC measurements in one patient. SDC " serum doxycycline concentration. Mean serum doxycycline concentration in mg/mL shown below figure. Dosage unknown during 11 SDC measurements in one patient.
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Discussion
Treatment based on SDC was associated with a lower hazard for disease-related events compared with treatment with a fixed doxycycline dose. The effect may be explained through better treatment accomplished by optimized dosage of doxycycline, or by better adherence to medication in patients with measurement of SDC. We hypothesized that treatment based on SDC could be a proxy for intensity of patient care, which may explain favourable outcomes for patients in whom treatment was based on SDC. Indeed, the ratio of number of phase I IgG antibody titre measurements and follow-up duration in weeks was higher in patients treated based on SDC. Adjustment for this ratio did not lead to different conclusions. This could be due to the fact that both parameters represent exactly the same underlying variable. However, the ratio was associated with all-cause mortality while SDC measurement was not. Therefore, the distribution of this variable is different from SDC measurement and we must conclude that increased intensity of patient care cannot explain the observed effect entirely. Measurement of SDC was not associated with all-cause mortality or PCR-positivity during treatment. The lack of an association between treatment based on SDC and all-cause mortality or PCR-positivity may be due to lack of power: we only observed 28 deaths within 1 year of stopping doxycycline plus hydroxychloroquine and 20 cases with PCR-positivity during treatment. Serum doxycycline concentrations in chronic Q fever
JAC
In earlier studies, SDC .5 lg/mL proved to be beneficial in terms of serological response. Here, to our knowledge, we provide the first study of the effect of treatment based on SDC on clinical endpoints, which makes this a unique study. Due to the retrospective origin of this study, it was not possible to draw conclusions on the classical dose-response relationship. Clinicians titrate doxycycline dosage up to SDC of .5 lg/mL, in accordance with recommendations in the literature, or address incompliance in order to improve SDC. 9, 10 The fact that no differences in SDC were observed under different doxycycline dosages supports the hypothesis that clinicians in practice aim at values .5 lg/mL. This leads to bias when assessing the correlation between SDC values and clinical outcomes: in patients with the most severe disease, clinicians will perhaps aim for higher SDC values. Therefore, higher SDC values will be associated with worse outcomes, probably owing to reverse causality: in patients with most severe disease, SDC is titrated up to higher values. Therefore, we decided to assess the effect of a treatment strategy in which dosage and coaching of patients with regard to compliance is based on SDC, instead of evaluating the actual SDC values.
Besides the problems with assessing the relationship between SDC values and clinical outcomes, there may be a risk of bias caused by confounding by indication when studying the effect of measuring any SDC as well. Clinicians may measure SDC more often in patients with more pronounced disease or more complications. However, we observed an effect in the opposite direction: in patients with no measurement of SDC, complications occurred more frequently than in patients with SDC measured. The strength of the effect and relationship between SDC measurement and the other outcomes may be underestimated by confounding by indication.
Another potential issue is that there is a 'learning effect' among clinicians: the more patients they have treated over time, the more experience they have gained and the better they are able to manage these patients. Theoretically, this may result in an increase of the proportion of patients in whom SDC was measured over time. However, we did not observe an evident effect of time on the proportion of patients with SDC measured (although the numbers in the group of patients without measurement of SDC are small), leading to less favourable treatment outcome for these patients.
Finally, for this analysis, we only included patients treated with the combination of doxycycline and hydroxychloroquine. Therefore, it is uncertain whether these results are generalizable to patients treated with doxycycline monotherapy or doxycycline combined with other antibiotics.
Altogether, SDC measurement seems beneficial during treatment for chronic Q fever. Therefore, we recommend measuring of SDC during treatment of chronic Q fever with doxycycline and hydroxychloroquine. We advise aiming for SDC .5 lg/mL because clinicians strived for SDC values .5 lg/mL in this study, and this strategy was successful. No literature is available on upper target levels during treatment of chronic Q fever. From clinical van Roeden et al.
experience, we advise clinicians to strive for values .5 lg/mL but ,10 lg/mL. The recommendation on the upper target range is not evidence-based: there is no literature on toxic SDC values during prolonged treatment with doxycycline.
In conclusion, treatment based on SDC was associated with a lower hazard for disease-related events, but not for all-cause mortality or PCR-positivity. Intensity of patient care could not entirely explain the association we found, suggesting that SDC-based dosing itself decreases the risk for disease-related events in these patients, potentially through more optimal dosing or through improved compliance. We therefore recommend measurement of SDC and to strive for SDC .5 lg/mL and ,10 lg/mL during treatment of chronic Q fever. Serum doxycycline concentrations in chronic Q fever JAC
